Browsing Caprisa (Centre for the Aids programme of research in South Africa) by Title
Now showing items 99-118 of 448
-
Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial: response to O’Hagan et al.
(Lippincott Williams & Wilkins., 2012)No abstract available. -
Decreased incidence of dual infections in South African subtype C-infected women compared to a cohort ten years earlier.
(Mary Ann Liebert., 2011)Previously, we determined the incidence of dual infections in a South African cohort and its association with higher viral setpoint. Ten years later, we compare the incidence and impact of dual infections at transmission ... -
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
(American Association for the Advancement of Science., 2012)Serum characterization and antibody isolation are transforming our understanding of the humoral immune response to viral infection. Here, we show that epitope specificities of HIV-1–neutralizing antibodies in serum can be ... -
Design challenges facing clinical trials of the effectiveness of new HIV prevention technologies.
(Lippincott Williams & Wilkins., 2012)Recent successes of antiretroviral pre-exposure prophylaxis (PrEP) in preventing HIV infection have raised questions whether further placebo controlled trials of new HIV-prevention technologies are ethically justifiable. ... -
Determinants of optimal adherence over time to antiretroviral therapy amongst HIV positive adults in South Africa : a longitudinal study.
(Springer Verlag., 2011)Highly active antiretroviral therapy (HAART) requires strict adherence to achieve optimal clinical and survival benefits. A study was done to explore the factors affecting HAART adherence among HIV positive adults ... -
Development of broadly neutralizing antibodies from autologous neutralizing antibody responses.
(Lippincott Williams & Wilkins., 2014)Abstract available in pdf. -
The development of CD4 binding site antibodies during HIV-1 infection.
(American Society for Microbiology., 2012)Broadly neutralizing antibodies to the CD4 binding site (CD4bs) of gp120 are generated by some HIV-1-infected individuals, but little is known about the prevalence and evolution of this antibody response during the course ... -
Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial.
(PLOS ONE., 2013)Background: Accurate methods of HIV incidence determination are critically needed to monitor the epidemic and determine the population level impact of prevention trials. One such trial, Project Accept, a Phase III, ... -
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
(Macmillan Publishers Limited., 2014)Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the developmental pathway by which such ... -
The Diagnostic Accuracy of Urine Lipoarabinomannan Test for Tuberculosis Screening in a South African Correctional Facility.
(Public Library of Science., 2015)Abstract available in pdf. -
Differences in HIV-1 neutralization breadth in two geographically distinct cohorts in Africa.
(Oxford University Press., 2015)Abstract available in pdf. -
Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point.
(American Society for Microbiology., 2014)Defining the characteristics of HIV-specific CD8(+) T cell responses that lead to viral control is crucial for vaccine development. We evaluated the differential impact of magnitude, polyfunctional capacity, and specificity ... -
Disclosure of HIV status: experiences of patients enrolled in an integrated TB and HAART programme in South Africa.
(NISC & Taylor & Francis, 2009)The convergence between the tuberculosis (TB) and HIV epidemics has led to studies investigating strategies for integrated HIV and TB care. We present the experiences of a cohort of 17 patients enrolled in the first ... -
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.
(Springer., 2014)Abstract available in pdf. -
Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel.
(Nature., 2016)Abstract available in PDF file. -
Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?
(Elsevier., 2012)Background: Increased sexual risk behaviour in participants enrolled in HIV prevention trials has been a concern. The HVTN 503/Phambili study, a phase 2B study of the Merck Ad-5 multiclade HIV vaccine in South Africa, ... -
Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
(Elsevier., 2018)Abstract available in pdf. -
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
(Elsevier., 2011)No abstract available. -
A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.
(Informa Healthcare., 2011)Introduction: More than a million people acquire HIV infection annually. Pre-exposure prophylaxis (PrEP) using antiretrovirals is currently being investigated for HIV prevention. Oral and topical formulations of tenofovir ... -
Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa : implications for future treatment options.
(Lippincott Williams & Wilkins., 2011)Background: Drug resistance poses a significant challenge for the successful application of highly active antiretroviral therapy (HAART) globally. Furthermore, emergence of HIV-1 isolates that preferentially use CXCR4 as ...